“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...

EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...

Black men often cite not being asked as the primary reason for not participating in prostate cancer clinical trials. Only 10.4% of surveyed Black men with prostate cancer had participated in clinical ...

"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...

Urology Coding Q&A: Can G2211 be reported regardless of payer?

Urology Coding Q&A: Can G2211 be reported regardless of payer?

"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...

"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...

“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS.

"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of ...